CN Patent

CN118043305A — 尼洛加司他的合成

Assigned to Springworths Treatment Co ltd · Expires 2024-05-14 · 2y expired

What this patent protects

本公开涉及合成(S)‑2‑(((S)‑6,8‑二氟‑1,2,3,4‑四氢萘‑2‑基)氨基)‑N‑(1‑(2‑甲基‑1‑(新戊基氨基)丙‑2‑基)‑1H‑咪唑‑4‑基)戊酰胺(“尼洛加司他”)的方法。

USPTO Abstract

本公开涉及合成(S)‑2‑(((S)‑6,8‑二氟‑1,2,3,4‑四氢萘‑2‑基)氨基)‑N‑(1‑(2‑甲基‑1‑(新戊基氨基)丙‑2‑基)‑1H‑咪唑‑4‑基)戊酰胺(“尼洛加司他”)的方法。

Drugs covered by this patent

nirogacestat-hydrobromide (NIROGACESTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN118043305A
Jurisdiction: CN
Classification: —
Expires: 2024-05-14
Drug substance claim: No
Drug product claim: No
Assignee: Springworths Treatment Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.